Appendix 4E and Annual Report to Shareholders 2023
Filed with ASX · · 65 pages · English
Clinuvel Pharmaceuticals Limited on 6ix
Story so far
Earlier from Clinuvel Pharmaceuticals
- Quarterly Activities/Appendix 4C Cash Flow Report
- Quarterly Activities/Appendix 4C Cash Flow Report Re-issued
- S&P DJI Announces September 2022 Quarterly Rebalance
- Appendix 4E and Annual Report 2022
- Positive Final Results in Stroke Study CUV801
Later from Clinuvel Pharmaceuticals
- CUV Appendix 4D Half Year Report
- SCENESSE provides photoprotection in variegate porphyria
- New case of SCENESSE efficacy in vitiligo presented at AAD
- CLINUVEL initiates on market share buy-back program
- afamelanotide in fair-skinned Parkinsons patients
Follow Clinuvel Pharmaceuticals into a list and get an email when it puts out news.
Follow Clinuvel Pharmaceuticals